Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility ...
Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies. People living with HIV have historically been excluded from many clinical trials assessing new cancer ...
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen. A frontline PARP inhibitor triplet for ...
PRV111, a nanoengineered, cisplatin-releasing transmucosal patch, achieved a 95.5% pathologic complete response (pCR) rate in patients with non-invasive oral cancer or high-grade dysplasia (HGD), ...
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years. Dan Costin, ...
The phase 2/3 NRG GU002 trial (NCT03070886) evaluated whether adding 6 cycles of docetaxel after radiation and androgen ...
Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the ...
Callander, MD, discussed the rationale for a quadruplet regimen being evaluated in patients with relapsed/refractory multiple ...
Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as ...
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma. Chari is a professor of clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results